Allergy Therapeutics (LSE:AGY) Total Stockholders Equity : £26.46 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics Total Stockholders Equity?

Allergy Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £26.46 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Allergy Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was £0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Allergy Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.37.

Allergy Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Allergy Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Total Stockholders Equity Chart

Allergy Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Stockholders Equity

Get a 7-Day Free Trial

37.56

43.78

48.54

37.77

2.07

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															54.97	37.77	37.96	2.07	26.46

Allergy Therapeutics (LSE:AGY) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Allergy Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(26.462	-	0)	/	4766.44
	=	0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Allergy Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.75	+	8.1)	/	26.462
	=	0.37

Allergy Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (LSE:AGY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (LSE:AGY) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

HHU:Germany

Address

Dominion Way, Worthing, West Sussex, GBR, BN14 8SA

Website

https://www.allergytherapeutics.com

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (LSE:AGY) Headlines

No Headlines